AU2017321965A1 - nNif and nNIF-related peptides and related methods - Google Patents

nNif and nNIF-related peptides and related methods Download PDF

Info

Publication number
AU2017321965A1
AU2017321965A1 AU2017321965A AU2017321965A AU2017321965A1 AU 2017321965 A1 AU2017321965 A1 AU 2017321965A1 AU 2017321965 A AU2017321965 A AU 2017321965A AU 2017321965 A AU2017321965 A AU 2017321965A AU 2017321965 A1 AU2017321965 A1 AU 2017321965A1
Authority
AU
Australia
Prior art keywords
nnif
nrp
seq
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017321965A
Other languages
English (en)
Inventor
Joshua Schiffman
Andrew S. Weyrich
Christian Con YOST
Guy A. Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2017321965A1 publication Critical patent/AU2017321965A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2017321965A 2016-09-02 2017-09-05 nNif and nNIF-related peptides and related methods Abandoned AU2017321965A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662383243P 2016-09-02 2016-09-02
US62/383,243 2016-09-02
US201762492019P 2017-04-28 2017-04-28
US62/492,019 2017-04-28
PCT/US2017/050072 WO2018045371A2 (en) 2016-09-02 2017-09-05 nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS

Publications (1)

Publication Number Publication Date
AU2017321965A1 true AU2017321965A1 (en) 2019-04-04

Family

ID=61309026

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017321965A Abandoned AU2017321965A1 (en) 2016-09-02 2017-09-05 nNif and nNIF-related peptides and related methods

Country Status (13)

Country Link
US (1) US10857201B2 (enExample)
EP (1) EP3506924A4 (enExample)
JP (1) JP2019534247A (enExample)
KR (1) KR20190045271A (enExample)
CN (1) CN109937047A (enExample)
AU (1) AU2017321965A1 (enExample)
BR (1) BR112019004299A2 (enExample)
CA (1) CA3035770A1 (enExample)
MX (1) MX2019002479A (enExample)
RU (1) RU2019109049A (enExample)
SG (1) SG11201901830UA (enExample)
WO (1) WO2018045371A2 (enExample)
ZA (1) ZA201901942B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230158108A1 (en) * 2020-05-04 2023-05-25 University Of Utah Research Foundation Immunothrombosis in covid-19 acute respiratory distress syndrome
CN117004744B (zh) * 2022-04-27 2024-05-24 数字碱基(南京)科技有限公司 一种基于血浆微生物dna特征的肺癌预后评估方法及模型

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US9308235B2 (en) * 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP4219534A3 (en) * 2013-07-08 2023-09-27 The University of Utah Research Foundation Methods for treatment of and prophylaxis against inflammatory disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324801B2 (en) 2016-09-02 2022-05-10 University Of Utah Research Foundation NNIF and nNIF-related peptides and related methods

Also Published As

Publication number Publication date
BR112019004299A2 (pt) 2019-05-28
KR20190045271A (ko) 2019-05-02
CA3035770A1 (en) 2018-03-08
ZA201901942B (en) 2020-10-28
RU2019109049A (ru) 2020-10-05
EP3506924A4 (en) 2020-05-20
SG11201901830UA (en) 2019-03-28
US10857201B2 (en) 2020-12-08
WO2018045371A2 (en) 2018-03-08
US20190201487A1 (en) 2019-07-04
JP2019534247A (ja) 2019-11-28
MX2019002479A (es) 2019-09-19
WO2018045371A3 (en) 2018-04-12
CN109937047A (zh) 2019-06-25
RU2019109049A3 (enExample) 2020-12-24
EP3506924A2 (en) 2019-07-10

Similar Documents

Publication Publication Date Title
Yost et al. Neonatal NET-inhibitory factor and related peptides inhibit neutrophil extracellular trap formation
Gong et al. Mechanism of lactic acidemia-promoted pulmonary endothelial cells death in sepsis: role for CIRP-ZBP1-PANoptosis pathway
US20230381290A1 (en) Methods for treatment of and prophylaxis against inflammatory disorders
Genschmer et al. Activated PMN exosomes: pathogenic entities causing matrix destruction and disease in the lung
Malerba et al. Epidermal hepcidin is required for neutrophil response to bacterial infection
US8304389B2 (en) Methods of inhibiting cell death or inflammation in a mammal by administering a BCL protein
US10857201B2 (en) NNIF and nNIF-related peptides and related methods
JP2024160399A (ja) 脳機能調整剤、およびこれを含む飲食品
US11324801B2 (en) NNIF and nNIF-related peptides and related methods
Haddox et al. Inhibitory effect of a complementary peptide on ulceration in the alkali-injured rabbit cornea
Yeh et al. Cisd2 delays atrial aging via a modulation of calcium homeostasis that mitigates atrial myopathy
US7939064B2 (en) Phospholipase(s) and use(s) thereof
HK40004861A (zh) Nnif和nnif相关肽以及相关方法
US20090162379A1 (en) Inhibitors of S. aureus SdrD protein attachment to cells and uses therefor
Kerreneur et al. Non-canonical caspase-8 activation by cathepsin B drives anti-inflammatory human macrophage polarization
US20210169985A1 (en) Methods for treating gram positive bacterial infection
TW202615649A (zh) 人類滋養層幹細胞分泌體、外泌體及其用途

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted